Literature DB >> 3933027

Overestimations of hypnotic drug effects by insomniacs--a hypothesis.

D Schneider-Helmert.   

Abstract

Data on subjective estimates and polygraphic measures of total sleep time and sleep latency were collected from the literature and analyzed for accordance or discrepancy between subjective and objective (EEG-based) mean values in experiments on acute treatment of insomnia by benzodiazepine hypnotics. In baseline placebo conditions there was a tendency to overestimate the disturbance of sleep. After drug administration, sleeping was overestimated. Within both subjective and objective measures, the magnitude of drug effects was correlated with poor initial sleep. If discrepancies between subjective and objective measures per se were analyzed, a number of correlational factors led to the hypothesis that psychological characteristics of a given population play a primary role: populations overestimating their sleep disturbances also tended to overestimate hypnotic drug effects. However, overestimations of drug effects were not correlated with type of drug or objective measures of sleep disturbance before treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933027     DOI: 10.1007/bf00431788

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

1.  Midazolam: dose-response studies of effectiveness and rebound insomnia.

Authors:  A Kales; C R Soldatos; E O Bixler; P J Goff; A Vela-Bueno
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

2.  Sleep laboratory and performance evaluation of midazolam in insomniacs.

Authors:  P Hauri; T Roth; M Sateia; F Zorick
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Effects of midazolam on sleep in normal subjects.

Authors:  J Krieger; P Mangin; D Kurtz
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

4.  Quazepam, a new benzodiazepine hypnotic: intermediate-term sleep laboratory evaluation.

Authors:  A Kales; M B Scharf; C R Soldatos; E O Bixler; S B Bianchi; P K Schweitzer
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

5.  Lorazepam-efficacy, side effects, and rebound phenomena.

Authors:  M B Scharf; A Kales; E O Bixler; J A Jacoby; P K Schweitzer
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

6.  Dose-response studies of quazepam.

Authors:  A Kales; M B Scharf; E O Bixler; P K Schweitzer; J A Jacoby; C R Soldatos
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Quazepam and flurazepam: long-term use and extended withdrawal.

Authors:  A Kales; E O Bixler; C R Soldatos; A Vela-Bueno; J Jacoby; J D Kales
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

8.  Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia.

Authors:  A Kales; E O Bixler; C R Soldatos; D J Mitsky; J D Kales
Journal:  J Clin Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.126

9.  Long-term sleep laboratory evaluation of flunitrazepam.

Authors:  M B Scharf; E O Bixler; A Kales; C R Soldatos
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

10.  The effects of flurazepam, lorazepam, and triazolam on sleep and memory.

Authors:  T Roth; K M Hartse; P G Saab; P M Piccione; M Kramer
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  3 in total

1.  Objective vs. subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect?

Authors:  Catherine McCall; W Vaughn McCall
Journal:  J Clin Sleep Med       Date:  2012-02-15       Impact factor: 4.062

Review 2.  Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia.

Authors:  S I Ankier; K L Goa
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

Review 3.  Guidelines for the rational use of benzodiazepines. When and what to use.

Authors:  H Ashton
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.